Opendata, web and dolomites

MiRCHOL SIGNED

Mechanistic and therapeutic implications of microRNA deregulation for drug resistance in bile duct cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MiRCHOL project word cloud

Explore the words cloud of the MiRCHOL project. It provides you a very rough idea of what is the project "MiRCHOL" about.

researcher    genome    reflecting    resistance    cancer    tumor    insights    emphasized    independent    metastasis    dismal    pattern    pathogenesis    treatment    plus    orchestrating    consequence    drug    outcome    scientific    modulate    besides    skills    rate    integrate    translational    matched    mir    micrornas    medicine    urgently    options    supervise    transcriptomes    70    expert    completion    clinical    involvement    andersen    yield    gt    cholangiocarcinoma    expertise    heterogeneity    liver    chemoresistant    survival    patients    molecular    transferable    cca    incidence    unresectable    society    unclear    instability    therapy    expression    37       disease    progression    data    ing    doubled    diagnosis    dr    genes    world    chemoresistance    efficacy    achievement    editing    myself    alone    deregulation    patient    limited    multiple    regulate    hepatobiliary    characterization    cancers    deregulated    vast    linking    successful    last    expand    mortality    mirs    me    stage    complicating    genomic    crispr    hence   

Project "MiRCHOL" data sheet

The following table provides information about the project.

Coordinator
KOBENHAVNS UNIVERSITET 

Organization address
address: NORREGADE 10
city: KOBENHAVN
postcode: 1165
website: www.ku.dk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 200˙194 €
 EC max contribution 200˙194 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2020-07-23

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) coordinator 200˙194.00

Map

 Project objective

Cholangiocarcinoma (CCA) is a dismal type of liver cancer which incidence has more than doubled the last 20 years and mortality rate in Europe alone increased 37%, reflecting the limited treatment options. In >70% of patients CCA is unresectable due to advanced stage of disease at diagnosis, resulting in a 5% 5-year survival rate. CCA is characterized by molecular and clinical heterogeneity, complicating therapy and assessment of drug efficacy. Tumor heterogeneity is emphasized in limited response of therapy (drug resistance) and besides genomic instability a likely consequence of deregulated pathways under control of microRNAs (miRs). Each miR can regulate multiple genes/pathways, directly linking them to tumor heterogeneity. Deregulation of miRs can cause/control chemoresistance in other cancers, but in CCA their role is yet unclear. Thus, detailed characterization of miRs in CCA, focusing on their impact in drug resistance is urgently needed. Hence, I have 3 specific aims of this proposal: to 1) characterize the deregulated expression pattern of miRs involved in CCA pathogenesis and integrate this data with transcriptomes obtained from matched patients; 2) determine the role of deregulated miRs in control of chemoresistance, and 3) modulate by genome-editing key deregulated miR(s) targeting chemoresistant genes using the novel `CRISPR-Mir’ method. Achievement of these aims will yield key new insights into the role of miRs in orchestrating CCA progression and metastasis, as well as their involvement in drug resistance. My findings will have an impact on the society and in particular in patient outcome. Dr. Andersen, a world-wide expert in the molecular pathogenesis of CCA with a vast experience in genome medicine, will supervise the project. Successful completion of this proposal will enable me to expand my scientific expertise (plus technical and transferable skills) and to establish myself as an independent researcher in hepatobiliary and translational research.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIRCHOL" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIRCHOL" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PNAIC (2018)

Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological Responses

Read More  

InvADeRS (2019)

Investigating the Activity of transposon Derived Regulatory Sequences in the placenta

Read More  

MIGPSC (2018)

Shaping the European Migration Policy: the role of the security industry

Read More